Assembly Biosciences (ASMB) Hits New 1-Year High at $62.48
Assembly Biosciences Inc (NASDAQ:ASMB) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $62.48 and last traded at $62.61, with a volume of 242380 shares changing hands. The stock had previously closed at $58.14.
A number of research analysts have issued reports on ASMB shares. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Monday, January 15th. BidaskClub raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, January 30th. Jefferies Group raised their price objective on shares of Assembly Biosciences to $75.00 and gave the stock a “buy” rating in a research note on Thursday, March 8th. B. Riley initiated coverage on shares of Assembly Biosciences in a research note on Friday, January 5th. They set a “neutral” rating and a $35.00 price objective for the company. Finally, ValuEngine cut shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $54.25.
The firm has a market capitalization of $1,177.41, a P/E ratio of -21.50 and a beta of 0.57.
Institutional investors and hedge funds have recently modified their holdings of the company. Nationwide Fund Advisors purchased a new position in shares of Assembly Biosciences during the 2nd quarter worth approximately $161,000. Parametric Portfolio Associates LLC increased its stake in shares of Assembly Biosciences by 13.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 1,203 shares in the last quarter. Wells Fargo & Company MN acquired a new stake in Assembly Biosciences during the second quarter worth approximately $213,000. The Manufacturers Life Insurance Company boosted its position in Assembly Biosciences by 15,448.6% during the second quarter. The Manufacturers Life Insurance Company now owns 11,195 shares of the biopharmaceutical company’s stock worth $232,000 after acquiring an additional 11,123 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in Assembly Biosciences during the fourth quarter worth approximately $242,000. 77.26% of the stock is owned by institutional investors and hedge funds.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.